‘Dupixent revolutionary atopic dermatitis drug to end lack of fundamental treatment’

Korea Biomedical Review

29 January 2020 - Sanofi Genzyme exec stresses development of accurate pain index for patients.

Sanofi's Dupixent (dupilumab), the only biologic drug for atopic dermatitis, has finally won the local health insurance coverage for patients with serious atopic dermatitis this year.

The government recently designated Dupixent as the first medicine to apply an extended risk-sharing agreement, as social demand for the new drug was high. The government had applied RSA only to the treatments of severe and rare diseases until then.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder